Ozempic and Hamas deserve the same standard

The article discusses the legal implications of writing about Hamas and the weight-loss drug Ozempic, highlighting recent fines imposed on media for perceived promotional content about Ozempic. Journalists express disbelief at being penalized for factual reporting, questioning the restrictions on discussing prescription medications. The author contrasts this with new legislation aimed at prohibiting the glorification of terrorism, noting that the criteria for what constitutes glorification are vague. Other EU countries have clearer definitions for similar laws, making it easier for governments to intervene. The piece raises concerns about the potential chilling effect on journalism and public discourse regarding both health and terrorism.